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Abstract:  Pertussis  toxin  (PTX)  is  a  typical  A-B  toxin.  The  A-protomer  (S1  subunit) 
exhibits ADP-ribosyltransferase activity. The B-oligomer consists of four subunits (S2 to S5) 
and binds extracellular molecules that allow the toxin to enter the cells. The A-protomer 
ADP-ribosylates  the  α  subunits  of heterotrimeric Gi/o  proteins,  resulting  in the receptors 
being uncoupled from the Gi/o proteins. The B-oligomer binds proteins expressed on the cell 
surface,  such  as  Toll-like  receptor  4,  and  activates  an  intracellular  signal  transduction 
cascade. Thus, PTX modifies cellular responses by at least two different signaling pathways; 
ADP-ribosylation of the Gαi/o proteins by the A-protomer (Gi/o protein-dependent action) and 
the  interaction  of  the  B-oligomer  with  cell  surface  proteins  (Gi/o  
protein-independent action). 
Keywords: A-protomer; ADP-ribosylation; B-oligomer; Gi/o-dependent; Gi/o-independent; 
heterotrimeric G protein; G protein-coupled receptor; pertussis toxin; Toll-like receptor 4 
Abbreviations: AC, adenylyl cyclase; CHO, Chinese hamster ovary; CaMKII, calmodulin 
kinase II; CREB, cAMP response element-binding; 8-CPT, 8-(4-chlorophenylthio)-2'-O-
methyladenosine-3',5'-cyclic  monophosphate;  eEF2,  eukaryotic  elongation  factor;  Epac, 
exchange protein directly activated by cAMP; ERK, extracellular signal-regulated kinase; 
GPCRs,  G  protein-coupled  receptors;  Gi/oPCRs,  Gi/o  protein-coupled  receptors;  GPIb, 
glycoprotein Ib; MAPK, mitogen-activated protein kinase; NAD
+, nicotinamide adenine 
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dinucleotide; PKA, cAMP-dependent protein kinase; PTX, Pertussis toxin; TLR4, Toll-like 
receptor 4; HUVECs, human umbilical vein endothelial cells; SAA, serum amyloid A; 
SPC, sphingosylphosphorylcholine; TCR, T-cell receptor 
 
1. Introduction  
Bacterial pathogens utilize their toxins to modify or kill host cells. The bacterial ADP-ribosylating 
toxins are a large family of dangerous and lethal toxins that include pertussis toxin (PTX), cholera 
toxin, diphtheria toxin, and pseudomonas exotoxin A [1,2]. These toxins are found in a diverse range 
of bacterial pathogens and are the cytotoxic agents that cause severe infectious diseases including 
whooping cough, cholera, and diphtheria (Table 1). 
Table 1. Characteristics of ADP-ribosylating toxins from several virulent strains of bacteria. 
ADP-Ribosylating Toxin  Bacterium  Target  Pathological Effect 
Pertussis toxin  Bordetella pertussis  Cysteine residue of Gαi 
subfamily (Gαi, Gαo, and Gαt) 
except Gαz 
Gαi protein-receptor coupling  
is inhibited, and its signal 
transduction is blocked. 
Cholera toxin  Vibrio cholerae  Arginine residue of Gαs 
subfamily (Gαs and Gαolf) 
As GTPase activity of the 
stimulatory Gαs is inhibited, 
Gαs protein is permanently 
activated. 
Heat-labile enterotoxin  Escherichia coli  Arginine residue of Gαs 
subfamily (Gαs and Gαolf) 
As GTPase activity of 
stimulatory Gαs is inhibited, 
the Gαs protein is permanently 
activated. 
Diphtheria toxin  Corynebacterium 
diphtheirae 
Diphthamide of eEF2  Protein synthesis is blocked. 
Exotoxin A  Pseudomonas aeruginosa  Diphthamide of eEF2  Protein synthesis is blocked. 
eEF2 = eukaryotic elongation factor 2. 
Pertussis  toxin  (PTX)  is  the  ADP-ribosylating  toxin  produced  by  the  whooping  cough  causing 
bacterium  Bordetella  pertussis  [3].  PTX  catalyzes  the  ADP-ribosylation  of  the  α  subunits  of  the 
heterotrimeric Gi/o protein family (Gαi, Gαo, and Gαt; except Gαz), thereby preventing the G proteins 
from interacting with their cognate G protein-coupled receptors (GPCRs) [4]. ADP-ribosylation of the 
α subunit of heterotrimeric Gi/o proteins (Gαi/o) locks the α subunits into an inactive state (GDP-bound 
form), thus it is unable to inhibit adenylyl cyclase (AC). This modification of the Gαi/o proteins results 
in the enhanced accumulation of cAMP, which is one of the mechanisms by which PTX induces the 
various pathological effects in host cells.  
PTX is composed of an A-protomer and B-oligomer. The A-protomer exerts ADP-ribosyltransferase 
activity on the Gαi/o proteins, leading to inhibition of receptor-G protein coupling [5,6]. The B-oligomer 
of  PTX  recognizes  and  binds  carbohydrate-containing  receptors  that  deliver  A-protomer  into  the  
cytosol  [7]. Although  many  of the  effects  of PTX  are dependent on ADP-ribosylation of the  Gαi/o Toxins 2011, 3                        
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proteins, Gi/o protein-independent effects of PTX have also been reported. For example, interaction of the 
B-oligomer with receptors on certain eukaryotic cells can mediate biological effects that are independent 
of  the  catalytic  activity  of  A-protomer,  including  enhancement  of  immune  responses  [8–10],  an 
increase in adenosine A1 receptor density [11], and the activation of tyrosine kinase, mitogen-activated 
protein kinase (MAPK), and NF-κB [12–14]. Moreover, we recently demonstrated a novel function of 
PTX that induces up-regulation of angiotensin II type 1 receptor independently of ADP-ribosylation of 
Gαi/o  [15].  Thus,  PTX  can  mediate  biological  effects  through  at  least  two  signaling  pathways;  
(1)  Gi/o  protein-dependent  pathway  through  ADP  ribosylation  of  the  Gαi/o  proteins  and  (2)  Gi/o  
protein-independent pathway by the binding of B-oligomer to cell surface proteins such as Toll-like 
receptor 4 (TLR4) [15] but not GPCRs. 
In  this  paper,  we  review  our  current  understanding  of  the  Gi/o  protein-dependent  and  Gi/o  
protein-independent pharmacological effects of PTX.  
2. Structure of Pertussis Toxin 
The PTX molecule is a complex ADP-ribosylating toxin composed of five different subunits: S1, 
S2, S3, S4 and S5, presented in a ratio of 1:1:1:2:1 and arranged in the A-B architecture [16]. The  
A-protomer consists of a single S1 subunit that is responsible for ADP-ribosyltransferase activity [17], 
while the B-oligomer comprises S2, S3, S5, and two S4 subunits [18]. The A-protomer catalyzes the 
ADP-ribosylation of a cysteine residue in the α subunit of the heterotrimeric Gi/o protein subfamily, 
whereas the B-oligomer is responsible for binding to specific cell surface receptors and delivering the 
A-protomer into recipient cells [7]. 
The crystal structure of PTX [18] revealed that the B-oligomer is composed of 5 noncovalently 
linked subunits which are organized as a triangular platform around a single catalytic S1 subunit that is 
on the top of the platform (Figure 1). 
Exposing PTX to urea results in dissociation of the A-protomer (S1 subunit) from the B-oligomer 
and  breakdown  of  the  B-oligomer  into  three  moieties:  S2-S4  dimer,  S3-S4  dimer,  and  S5  
monomer [16]. These results suggest that the B-oligomer consists of two dimers, the S2-S4 and S3-S4 
dimers, which are held together by the S5 subunit. 
Figure 1. Pertussis toxin (PTX) structural organization. PTX contains five different subunits 
that  are  arranged in a typical  A-B structure.  The  A-protomer contains  an enzymatically 
active S1 subunit that is on the top of B-oligomer. The B-oligomer is composed of two 
dimers, S2-S4 and S3-S4 dimers, which are held together by the S5 subunit. 
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The  S2  and  S3  subunits  of  PTX  share  approximately  75%  nucleotide  and  70%  amino  acid  
homology [19,20]. Despite more than 75% sequence homology, structural and functional studies using 
site-directed mutagenesis of the S2 and S3 subunits have shown that the S2 subunit mediates binding 
to nonsialylated glycans, whereas S3 selectively binds sialylated oligosaccharides [21,22]. 
The S1 subunit of PTX contains regions of sequences homology to the catalytic portion of other 
ADP-ribosylating toxins such as the cholera toxin, enterotoxin, diphtheria toxin, and exotoxin A [1]. 
The carboxyl terminus of the S1 subunit is composed of 235 amino acid residues [23]. Previous studies 
have indicated that the carboxyl terminus is important in the interaction of the S1 subunit with the  
B-oligomer [24,25]. Residues 195 to 204 are required for optimal ADP-ribosylation of the α subunit of 
heterotrimeric Gi/o proteins. Residues 205 to 219 are linked to the catalytic region of S1 and are the  
B-oligomer-binding site of S1 subunit. Residues 220 to 235 are hydrophobic and are important for 
interaction of the S1 subunit with the B-oligomer [23]. 
The A protomer contains two cysteine residues at positions 41 and 201, which form disulfide bonds 
in the native PTX holotoxin. [26]. Reduction of this disulfide bond by dithiothreitol leads to a marked 
stimulation  of  S1  catalytic  activity,  which  coincides  with  a  release  of  the  S1  subunit  from  
B-oligomer [27]. Moreover, the presence of ATP leads to the dissociation of the S1 subunit from  
B-oligomer [28]. This dissociation makes the disulfide bond of the S1 subunit susceptible to cleavage 
by intracellular reducing compounds. 
3. ADP-Ribosylation Mechanism of PTX 
Following attachment of PTX to host cells, S2 and S3 subunits of B-oligomer bind to the exposed 
sugar residues of glycolipid (gangliosides) on the plasma membrane of host cells. The A-protomer  
(S1 subunit) penetrates through the membrane and is released from B-oligomer into the cytoplasm. 
However, the exact molecular events associated with the entry of PTX into host cells are not fully 
understood.  Once  inside  the  cell  the  A-protomer  ribosylates  specific  target  proteins  such  as  the  
α  subunit  of  heterotrimeric  Gi/o  proteins  (Figure  2)  through  its  ADP-ribosyltransferase  activity.  
ADP-ribosylation is also responsible for the actions of other bacterial ADP-ribosylating toxins, such as 
cholera toxin, diphtheria toxin, and exotoxin A. 
PTX catalyzes the cleavage of the C-N bond between carbon atom of ribose and nitrogen atom of 
nicotinamide and transfer the ADP-ribosyl moiety from nicotinamide adenine dinucleotide (NAD
+) to 
an acceptor molecule on the target protein (Figure 2). The target proteins for other ribosylating toxins 
include the eukaryotic elongation factor (eEF2) for diphtheria toxin [29] and arginine residue of the 
Gαs protein for cholera toxin, which, like the Gαi/o-protein target for PTX, are involved in cell signal 
transduction [30]. In the case of PTX, ADP-ribosylation of the Gαi/o-proteins prevents the coupling to 
their cognate GPCRs and consequently disrupts the signal transduction cascade [31,32]. Besides their 
function as ADP-ribosyl transferases, the ADP-ribosylating toxins also have NAD
+ glycohydrolase 
activity in the absence of an acceptor molecule [17]. However, this activity does not seem to contribute 
to any effects of PTX in the cell.  
The  amino  acid  ADP-ribosylated  by  PTX  is  cysteine,  which  is  located  four  residues  from  the 
carboxyl terminus of the α subunits of the Gi/o proteins [33]. The uncoupling of GPCR from the Gαi/o 
proteins results in disruption of the communication between receptor and the effector molecule AC. Toxins 2011, 3                        
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Thus, the Gαi/o protein is inactivated and cannot perform its normal function to inhibit AC. In this way 
it prevents the signal from Gi/oPCRs. Thus, the conversion of ATP to cAMP cannot be halted, resulting 
in excess intracellular cAMP level and the subsequent disruption of many cellular processes as shown 
in Figure 3. With the exception of Gαz, all members of the Gαi/o protein family are substrates for PTX. 
Figure 2. Schematic diagram of the ADP-ribosylation of α subunit of heterotrimeric Gi/o 
protein by pertussis toxin (PTX). PTX catalyzes the cleavage of the C-N bond between a 
carbon  atom  of  ribose  and  a  nitrogen  atom  of  nicotinamide,  and  transfers  the  
ADP-ribosyl moiety to an acceptor molecule. 
 
Figure  3.  Uncoupling  of  Gαi/o  proteins  from  their  cognate  G  protein-coupled  receptor 
(GPCR). Activation of GPCRs leads to dissociation of heterotrimeric G protein complex 
into Gαi/o and βγ subunit. The exchange of GTP from GDP results in activation of the 
inhibitory G protein (Gαi/o), thereby inhibiting adenylyl cyclase (AC) activity. When the  
A-protomer of PTX penetrates into the host cells, the Gαi/o is ADP-ribosylated at cysteine 
residue resulting in  inactivation of  Gαi/o. The inhibitory  effect  of  Gαi/o on AC  activity 
results  in  the  elevation  of  intracellular  cAMP  levels,  leading  to  activation  of  the  
cAMP-mediated signaling pathway. This enhanced pathway by PTX is recognized as the 
Gi/o protein-dependent pathway. 
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4. Gi/o Protein-Dependent Actions of PTX 
The  A-protomer  (S1  subunit)  of  PTX  catalyzes  the  ADP  ribosylation  of  the  membrane-bound 
regulatory Gi/o proteins resulting in inactivation, preventing them from inhibiting AC. As the inhibition 
of cAMP production by inhibitory GPCRs is only abolished by PTX, PTX treatment results in the 
enhancement of stimulatory GPCR-induced cAMP production. It is possible that the biological effects 
of PTX are a result of the disruption of the cAMP-mediated signaling pathway. As the Gi/o proteins are 
expressed in various tissues, the effects of PTX are observed in almost all cells. Some of the affected 
cells include the β-cells of pancreatic islets (hence the former name of PTX is islet-activating protein), 
adipocytes,  macrophages,  lymphocytes,  and  other  cells  that  cause  paroxysms  and  neurological 
disturbance. The ADP-ribosylation of the Gi/o proteins by PTX is irreversible. As a result, restoration 
of Gi/o function in the cells is dependent on Gi/o protein replacement of ADP-ribosylated Gi/o proteins 
with new proteins. Unlike cholera toxin, which acts to inhibit GTPase activity of the Gs protein, PTX 
does not affect basal GTPase activity of the Gi/o proteins, only receptor-stimulated GTPase. 
The biological effects of PTX that result from  ADP-ribosylation of the Gαi/o proteins  are very 
diverse,  some  of  which  can  be  attributed  to  the  ADP-ribosylation  of  the  α  subunits  of  the 
heterotrimeric Gi/o protein family, as shown in Table 2.  
Table 2. Gαi/o protein family. 
α Subunit  Amino Acid  Expression [34,35]  Effect on Effectors  Toxin (Site of Action)  
αo  354  Heart, neurons, 
neuroendocrine 
cells 
Inhibition of AC activity [36] 
Inhibition of Ca
2+ channel [39] 
Activation of K
+ channel [40] 
PTX at cysteine 351 [1,37,38] 
αi1-αi3  354  Neurons and 
ubiquitous 
Inhibition of AC activity [41] 
Inhibition of Ca
2+ channel [39,42] 
Activation of K
+ channel [40,43] 
PTX at cysteine 351 [1,37,38] 
αz  355  Platelets  Inhibition of AC activity [44] 
Inhibition of Ca
2+ channel [45] 
Activation of K
+ channel [40] 
-(cyteine modified by PTX 
does not present) [46] 
αt  350  Rod/cone outer 
segments 
Activation of cGMP-PDE [47]   PTX at cysteine 351 [37,38] 
CTX at arginine147 [37]  
αgust  353  Taste buds; sweet 
and/or bitter 
Activation of cGMP-PDE [48]  PTX at cysteine 350 [37,38]  
AC: adenylyl cyclase; PDE: phosphodiesterase. 
Pancreatic cells show increased insulin secretion upon treatment with PTX [37]. Moreover, PTX 
inhibits insulin-stimulated autophosphorylation of insulin receptor by inactivation of insulin receptor 
kinase. Treatment of cells with the catalytically inactive B-oligomer had no effect on insulin receptor 
kinase activity [49]. These results suggest that PTX can modulate insulin receptor signaling at receptor 
level. The lipolytic action of PTX has been used as a sensitive assay for the action of toxin, and is 
caused by PTX-catalyzed ADP ribosylation of the Gαi proteins in adipocytes. Adenosine is produced 
in vitro as one of the ATP degradation products during preparation of adipocytes from fat pads by the 
collagenase digestion method, and adenosine inhibits AC via the Gαi [2,50]. As lipolysis is enhanced Toxins 2011, 3                        
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by the increase in intracellular cAMP, inhibition of adenosine receptor-Gi/o coupling by PTX results in 
enhanced cAMP accumulation, leading to increased lipolysis. 
In vivo administration of PTX induces lymphocytosis, a hallmark of systemic pertussis in children. It 
also causes hyperinsulinemia and hypoglycemia, as well as modification of histamine sensitization [2]. 
In addition, PTX, but not a noncatalytic mutant of PTX, inhibits neutrophil migration to rat peritoneal 
cavities in response to lipopolysaccharide [51]. The increase in skin vascular permeability induced by 
leukotriene B4 is also inhibited by PTX only, not a catalytically inactive mutant. These results suggest 
that  PTX  inhibits  neutrophil  migration  and  vascular  permeability  in  vivo  and  these  effects  are 
dependent on the ADP-ribosyltransferase activity of the A-protomer. 
Ligand binding to inhibitory GPCRs leads to activation of the Gi/o proteins and then causes the 
dissociation of heterotrimeric Gi/o proteins into an activated αi/o subunit and a βγ subunit. The activated 
Gαi/o subunits (GTP-bound form) inhibit AC activity, resulting in the decrease of intracellular cAMP 
level  [30].  This  attenuates  the  cAMP-mediated  signaling  pathway.  Treatment  of  NG108-15  cells 
(neuroblastoma-glioma  hybrid  cells)  with  PTX  attenuates  receptor-mediated  inhibition  of  AC, 
resulting in inhibition of the opiate-stimulated GTPase activity. Moreover, this inhibition effect by 
PTX requires NAD
+, emphasizing that this effect of PTX is mediated by ADP- ribosylation of the 
Gαi/o  proteins.  The  Gαi/o  proteins  are  ADP-ribosylated  by  A-protomer,  inhibiting  the  GDP-GTP 
exchange of the Gi/o proteins by GPCRs. The α subunit is locked in the inactive GDP-bound state 
resulting in the enhanced increase in cAMP level by stimulatory GPCRs. Thus, Gi/o protein-dependent 
effects of PTX are mainly mediated by cAMP action. Cyclic AMP is formed from ATP by the action 
of AC and degraded to AMP by cAMP phosphodiesterase [52]. Most effects of cAMP in animal cells 
are mediated by the action of cAMP-dependent protein kinase (PKA). The inactive form of PKA is a 
tetramer  consisting  of  two  catalytic  and  two  regulatory  subunits.  The  binding  of  cAMP  to  the 
regulatory subunits leads to their dissociation from the catalytic subunits. The free catalytic subunits 
are then active and able to phosphorylate serine and threonine residues of their target proteins. The free 
catalytic subunit of PKA also translocates to the nucleus and phosphorylates the transcriptional factor 
CREB (cAMP response element-binding), leading to the activation of cAMP-inducible genes [53]. 
Such regulation of gene expression by cAMP plays important roles in controlling the proliferation, 
survival, and differentiation of a wide variety of animal cells. Previous studies have identified a family 
of molecules known as Epac (exchange protein directly activated by cAMP) that directly bind cAMP 
and exhibit guanine nucleotide exchange factor activity toward Rap1 [54,55]. The binding of cAMP or 
the  selective  cAMP  analogue  8-CPT  (8-(4-chlorophenylthio)-2'-O-methyladenosine-3',5'-cyclic 
monophosphate) to Epac leads to activation of calmodulin kinase II (CaMKII)-dependent signaling 
pathways  including  the  release  of  Ca
2+  from  sarcoplasmic  reticulum  [56]  and  the  increased 
phosphorylation  of  phospholamban  [57].  However,  whether  the  increase  in  cAMP  level  by  
PTX-catalyzed ADP-ribosylation of the Gαi/o proteins activates this Epac-mediated CaMKII signaling 
pathway remains to be elucidated. Toxins 2011, 3                        
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5. Gi/o Protein-Independent Actions of PTX 
ADP-ribosylation of the Gαi/o proteins does not account for all responses by the interactions of PTX 
with  host  cells.  PTX  is  reported  to  be  a  T-cell  mitogen  [7].  This  action  can  be  reproduced  by  
B-oligomer alone suggesting that B-oligomer itself may induce the mitogenic action independent of A-
protomer-induced ADP-ribosylation of the Gi/o proteins. Several other Gi/o protein independent actions 
of PTX have been reported, such as enhancement of immune responses [8–10], increase in adenosine 
A1 receptor density [11], and activation of tyrosine kinase, MAPK, and NF-κB [12–14]. Recently, we 
demonstrated that the B-oligomer of PTX induces Rac activation through a pathway independent of 
ADP-ribosylation  of  the  Gαi/o  proteins  [15].  PTX  increases  IL-1β  induction  through  sequential 
activation of TLR4, Rac, NADPH oxidase, and NF-κB, which leads to up-regulation of angiotensin II 
type 1 receptor. Thus, PTX binds to two binding sites; one is TLR4 which activates Rac, and another is 
the binding site that is required for the entry of PTX into the cells to ADP-ribosylate the Gαi/o [15]. 
Interestingly, both the S1 mutant of PTX and the B-oligomer completely reproduced several effects 
of  native  PTX  (holotoxin)  action.  For  example,  PTX-induced  extracellular  signal-regulated  kinase 
(ERK) activation of endothelial cell is entirely independent of ADP-ribosylation of the Gαi/o [58]. 
However,  inactivation  of  Gαi  proteins  by  PTX  inhibits  serum  amyloid  A  (SAA)-mediated  ERK 
activation in human umbilical vein endothelial cells (HUVECs) [59]. Preincubation of HUVECs in 
PTX (100 ng/mL) prior to sphingosylphosphorylcholine (SPC) stimulation markedly reduces the levels 
of phosphorylated MAPKs including ERK, indicating that Gαi proteins have a role in SPC-induced 
ERK activity [60]. Thus it is not clear what causes the difference in activation versus inhibition of 
ERK  activity.  One  possibility  could  be  derived  from  the  differential  cellular  mechanisms  which 
regulate ERK activity. 
Moreover,  the  B-oligomer  alone  was  as  effective  as  PTX  in  inducing  glucose  oxidation  in  rat 
adipocytes [7]. It was also reported that the binding of the B-oligomer to eukaryotic cells can alter 
cellular function independently of ADP-ribosylation. For example, PTX has been shown to bind to 
glycoprotein  Ib  (GPIb)  on  human  platelets,  leading  to  subsequent  platelet  aggregation  [61].  The 
purified B-oligomer also induces mitogenic stimulation of human T cells [62,63], enhances glucose 
oxidation in adipocytes [64], induces dendritic cell maturation in a TLR4-dependent manner [14], and 
associates with T-cell receptor complex to initiate signal transduction in T-lymphocytes [65]. 
Upon prolonged incubation (at least 1 or 2 h) with PTX, the A-protomer is internalized by certain 
cells and subsequently activated by cleavage of the disulfide bond. The A-protomer then catalyzes the 
transfer of an ADP-ribose moiety from endogenous NAD
+ to a carboxyl terminal cysteine residue in 
the Gαi/o proteins (Figure 2). A previous study reported that PTX completely ADP-ribosylated the 
Gαi/o proteins at 10 ng/mL within 3 h in Chinese hamster ovary (CHO) cells [66]. ADP-ribosylation of 
the  Gi/o  proteins  disrupts  their  interaction  with  various  inhibitory  GPCRs,  leading  to  blockade  of 
certain transmembrane signaling process and eventually cellular intoxication [67]. In addition to its 
delayed  inhibitory  effect  on  the  Gi/o  proteins,  PTX  has  also  been  shown  to  elicit  rapid  responses  
(in minutes) in a variety of cell types [64], which may have profound pathological effects as important 
as its ADP-ribosylation activity. PTX was shown to bind to human platelet GPIb, inducing rapid 
platelet aggregation and an increase of intracellular Ca
2+ level [61,68]. Recent studies also reported 
that  the  B-oligomer  interacts  with  extracellular  receptors,  such  as  the  T-cell  receptor  (TCR),  and Toxins 2011, 3                        
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activates  an  intracellular  signal  transduction  pathway  by  inducing  and  interacting  with  the  T-cell 
receptor complex [65,69]. In contrast to the rapid and transient effects caused by B-oligomer, the  
A-protomer (catalytic S1 subunit) must penetrate into the cytoplasm of host cells to ADP-ribosylate 
and inactivate the Gαi/o proteins. This process can usually take hours, but permanently modifies G 
proteins [65,70]. It indicates that PTX-induced responses in T-cells can be divided into two phases: 
short-term by the B-oligomer, and long-term by the catalytic A-protomer. From these data, it has been 
concluded that Gi/o protein-dependent effects of PTX through ADP-ribosylation occur more slowly 
than Gi/o protein-independent effects of PTX through the B-oligomer (Table 3).  
PTX detoxified by formaldehyde treatment or genetic modification maintains its protein structure 
and the immunological properties, but not its enzymatic activity [71,72]. This detoxified PTX is able to 
activate TLR4 in monocyte derived dendritic cells, a property previously reported for fully active PTX 
and its B-oligomer [14]. A low dose of detoxified PTX efficiently triggers TLR4 signaling, while a 
high dose is necessary to activate both TLR4 and TLR2 [73]. This is the first report showing that 
detoxified PTX also triggers TLR2-mediated signal transduction pathway. As TLR4 plays an essential 
role in expansion of Th1/Th17 immunity, detoxified PTX may work as an alternative adjuvant to 
promote Th1/Th17 responses.  
Interestingly, a previous study showed that while both PTX and the B-oligomer induce dendritic 
cell maturation, the induction of cytokines that are produced differ [14]. However, the effect of both 
PTX and its B-oligomer on dendritic cell maturation was dependent on TLR4 [74]. It is possible that 
the  differential  cytokine  production  of  dendritic  cells  by  PTX  and  the  B-oligomer  are  due  to  the 
differences  in  their  utilization  of  TLR4-mediated  intracellular  signaling  pathways,  which  may  be 
accounted for by both ADP-ribosylation-dependent and -independent responses. 
The toxic effects mediated by catalytic activity of the native PTX (holotoxin) occurs at very low toxin 
concentrations and appears to alter the function of tissues and organs very distal from the site of bacterial 
growth. In contrast, effects of PTX mediated by interaction of the B-oligomer with many cell surface 
proteins  require  higher  doses  of  the  toxin  [65].  For  example,  the  B-oligomer  of  PTX  caused 
concentration-dependent platelet activation, as determined by increasing intracellular Ca
2+ concentration 
and dense granule secretion [61]. In addition to its role in delivering the S1 subunit into the cells,  
the  B-oligomer  elicits  biological  effects  such  as  an  increase  in  intracellular  Ca
2+,  activation  of  
T-lymphocytes  [62,75]  and  platelet  aggregation  [68].  These  B-oligomer-mediated  effects  may  be 
elicited  by  the  binding  of  the  B-oligomer  to  a  specific  receptor  and  require  significantly  higher 
concentrations of toxin than are necessary for the ADP-ribosyltransferase activity of the A-protomer. 
Moreover, it appears that most cells would be susceptible to PTX as a result of ADP-ribosylation of 
the Gαi/o proteins and that PTX holotoxin-mediated effects could occur at many sites in host cells [72]. 
Recent findings demonstrate that the Gi/o protein-dependent action of PTX (via ADP-ribosylation of 
Gαi/o) exhibits the differences in signaling pathway when compare to that of Gi/o protein-independent 
action of PTX (via B-oligomer) as summarized in Table 3. Toxins 2011, 3                        
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Table  3.  The  differences  in  characteristics  of  Gi/o protein-dependent  and  -independent 
effects of PTX. 
  Gi/o Protein-Dependent Effects of PTX  Gi/o Protein-Independent Effects of PTX 
Subunit  A-protomer (S1 subunit)  B-oligomer (S2-S3 dimer, S2-S5 dimer,  
and S5 monomer) 
Onset of action  Slow  Rapid 
Concentration of toxin 
to induce the effects 
Low  High 
Biological effects  Enhance insulin secretion [49] 
Inhibit lymphocyte and neutrophil  
migration [52,76] 
Inhibit enkephalin stimulation of  
GTPase [77] 
Inhibit autophosphorylation and activation  
of insulin receptor kinase [50] 
 
Induce dendritic cell maturation [14] 
Inhibit growth cone guidance [78] 
Induce myelomonocytic cell adhesion [79] 
Induce ERK1/2 activation in endothelial cell [59] 
Activate platelet aggregation [62,69] 
Activate T lymphocyte [66,80] 
Induce Th1/Th17 immune response through 
MAPK and IL-10 [74] 
Activate tyrosine kinase signaling [12] 
Inhibit Tat-induced TGF- β production [81] 
Inhibit HIV type 1 replication [82] 
6. Conclusions 
It is clear that PTX exhibits its various effects by eliciting at least two different signaling pathways 
(Figure  4).  One involves  the mobilization of the enzymatic  A-protomer into host cells leading  to  
the ADP-ribosylation of the α subunit of heterotrimeric Gi/o proteins [72]. This process called Gi/o  
protein-dependent effect of PTX, has a slow onset (at least 1-2 h) and requires a low concentration of 
the toxin. A second involves binding of the B-oligomer of PTX to several targeted proteins expressed 
on the cell surface such as TLR4 [15], GPIb [61], and TCR4 [65] initiating a series of rapid signaling 
events  that  require  a  higher  concentration  of  the  toxin.  Thus,  the  B-oligomer  of  PTX  appears  to 
activate Gi/o protein-independent signaling in a diverse array of cell types. 
It remains to be determined whether the binding site of PTX for the B-oligomer-mediated responses 
is the same as that of PTX to enter the cells for the A-protomer to ADP-ribosylate the Gi/o proteins. 
Another  concern  generated  from  these  findings  is  whether  the  B-oligomer-mediated  early 
transmembrane signaling events will influence the subsequent ADP-ribosylation of the Gαi/o proteins. 
The various cellular responses of PTX cannot be concluded simply by modification of the Gi/o proteins, 
as the B-oligomer of PTX can also elicit cellular responses. 
In this review, we summarize that PTX can mediate biological responses by at least two different 
signaling pathways including (1) Gi/o protein-dependent action of PTX through ADP-ribosylation of 
the  Gαi/o  proteins  and  (2)  Gi/o  protein-independent  action  of  PTX  through  the  binding  of  the  
B-oligomer with cell surface specific proteins (Figure 4). Toxins 2011, 3                        
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Figure 4. Gi/o protein-dependent and -independent effects of PTX. Following the binding 
of PTX to host cells, the A-protomer penetrates through the cell membrane. A-protomer is 
dissociated from B-oligomer and released into the cytoplasm. A-protomer then catalyzes 
the ADP-ribosylation of Gαi/o that leads to uncoupling of Gαi/o from its cognate inhibitory 
GPCRs.  The  inhibitory  effect  of  Gαi/o  on  AC  activity  is  then  halted,  resulting  in 
accumulation  of  cAMP.  This  action  of  PTX  results  in  disruption  of  cellular  function 
through cAMP-mediated signaling pathway (Gi/o protein-dependent effects). In a separate 
pathway, the B-oligomer binds to and interacts with several targeted proteins on the plasma 
membrane, leading to the induction of the biological responses that are independent of 
ADP-ribosylation of Gαi/o protein (Gi/o protein-independent effects). 
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